Marketing dimensions in the prescription pharmaceutical industry: a systematic literature review
暂无分享,去创建一个
Nick Lee | N. Lee | M. Štros | Michael Stros | M. Štros
[1] G. Kalyanaram,et al. Order-of-Entry Effects on Consumer Memory and Judgment: An Information Integration Perspective , 1992 .
[2] Stephen J. Hoch,et al. Managing What Consumers Learn from Experience , 1989 .
[3] Joshua P Cohen. The new Dutch health insurance system and its implications for pharmaceutical innovation , 2007 .
[4] Sandy Oliver,et al. Integrating qualitative research with trials in systematic reviews , 2004, BMJ : British Medical Journal.
[5] Daniel Hogan,et al. The 30-Sec Sale: Using Thin-Slice Judgments to Evaluate Sales Effectiveness , 2006 .
[6] R. Tallman,et al. Relationships of physicians with pharmaceutical sales representatives and pharmaceutical companies: an exploratory study. , 1996, Health marketing quarterly.
[7] Pierre Azoulay,et al. Do Pharmaceutical Sales Respond to Scientific Evidence , 2002 .
[8] J. R. Williams,et al. Direct-to-consumer advertising of prescription drugs. , 1995, Journal of health care marketing.
[9] Marcia Angell,et al. The Truth About the Drug Companies , 2004 .
[10] James J. Chrisman,et al. Order of market entry, competitive strategy, and financial performance , 1995 .
[11] Nicholas J. Ashill,et al. Pharmaceutical marketing return‐on‐investment: a European perspective , 2007 .
[12] R. Bond,et al. Sales, Promotion and Product Dif-ferentiation in Two Prescription Drug Markets , 1977 .
[13] Sridhar Narayanan,et al. Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions , 2004 .
[14] J. Lexchin. Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary. , 2009, Health policy.
[15] Maarten C. W. Janssen,et al. Early mover advantages: An empirical analysis of European mobile phone markets , 2008 .
[16] R. Schmalensee. Product Differentiation Advantages of Pioneering Brands , 1980 .
[17] B. Wernerfelt,et al. An Evaluation Cost Model of Consideration Sets , 1990 .
[18] B. Mintzes,et al. For and against: Direct to consumer advertising is medicalising normal human experience: For. , 2002, BMJ : British Medical Journal.
[19] E. Berndt,et al. Effects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants , 2004 .
[20] Mickey C. Smith. Principles of pharmaceutical marketing , 1969 .
[21] Kevin Lane Keller,et al. MARKETING MANAGEMENT 12e , 2006 .
[22] S. Hart,et al. Marketing Strategy and Planning in the UK Pharmaceutical Industry: Some Preliminary Findings , 1990 .
[23] W. T. Robinson,et al. Note: The Impact of Leadtime and Years of Competitive Rivalry on Pioneer Market Share Advantages , 1994 .
[24] 김정남. 고객과 지식 Marketing , 2003 .
[25] Preventing childhood obesity by reducing consumption of carbonated drinks: cluster randomised controlled trial , 2004, BMJ : British Medical Journal.
[26] S. Tagg,et al. A grounded theory of doctors' information search behaviour. Implications for information provision, pharmaceutical market entry and development , 2007 .
[27] Venkatesh Shankar,et al. Pioneers' Marketing Mix Reactions to Entry in Different Competitive Game Structures: Theoretical Analysis and Empirical Illustration , 1997 .
[28] A. Po. A PRACTICAL GUIDE TO UNDERTAKING A SYSTEMATIC OVERVIEW , 1997 .
[29] R. Cooper,et al. Major new products: What distinguishes the winners in the chemical industry? , 1993 .
[30] Richard Staelin,et al. Environment, Market Share, and Market Power , 1990 .
[31] K. Boulding,et al. Barriers to New Competition: Their Character and Consequences in Manufacturing Industries. , 1957 .
[32] Gerard J. Tellis,et al. First to Market, First to Fail? Real Causes of Enduring Market Leadership , 2006 .
[33] Elisabeth Honka,et al. The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. , 2005, Yale journal of health policy, law, and ethics.
[34] Lisa C . Troy,et al. Order of Entry and Business Performance: An Empirical Synthesis and Reexamination , 1995 .
[35] J. Rizzo,et al. Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs* , 1999, The Journal of Law and Economics.
[36] N. A. Nichols. Scientific management at Merck: An interview with CFO Judy Lewent , 1994 .
[37] Gilbert A. Churchill,et al. The Determinants of Salesperson Performance: A Meta-Analysis , 1985 .
[38] The order of entry effect in prescription (Rx) and over‐the‐counter (OTC) pharmaceutical drugs , 2008 .
[39] J. Lattin,et al. Investigating the relationship between time in market and pioneering advantage , 1994 .
[40] David H. Reiley,et al. The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry , 1994 .
[41] B. Glitz. The focus group technique in library research: an introduction. , 1997, Bulletin of the Medical Library Association.
[42] M. Lambkin. Order of entry and performance in new markets , 1988 .
[43] C. Simon,et al. Making more of pharma's sales force: pharmaceutical companies have lost their focus on doctors. The key to higher sales is regaining it , 2002 .
[44] F. Mosteller,et al. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. , 1992, JAMA.
[45] Füsun F. Gönül,et al. Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior , 2001 .
[46] Glen L. Urban,et al. Market Share Rewards to Pioneering Brands: An Empirical Analysis and Strategic Implications , 2015 .
[47] Yun Jung Lee,et al. Value‐driven consumer e‐health information search behavior , 2007 .
[48] Peter R.J. Trim,et al. A new product launch strategy (NPLS) model for pharmaceutical companies , 2005 .
[49] C. Fornell,et al. Sources of Market Pioneer Advantages in Consumer Goods Industries , 1985 .
[50] Z. Griliches,et al. Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. , 1997, The Rand journal of economics.
[51] Joel B. Cohen,et al. Alternative Models of Categorization: Toward a Contingent Processing Framework , 1987 .
[52] Jos Kleijnen,et al. The comprehensiveness of Medline and Embase computer searches , 1992, Pharmaceutisch Weekblad.
[53] D. Dogramatzis. Pharmaceutical Marketing: A Practical Guide , 2001 .
[54] M. Petticrew,et al. Systematic Reviews in the Social Sciences , 2006 .
[55] P. Kotler. A Generic Concept of Marketing , 1972 .
[56] G. Jin,et al. The Effects of Direct-to-Consumer Advertising in the Prescription Drug Markets , 2002 .
[57] R Hartley,et al. Scientific versus commercial sources of influence on the prescribing behavior of physicians. , 1982, The American journal of medicine.
[58] Barton A. Weitz,et al. The SOCO Scale: A measure of the customer orientation of salespeople. , 1982 .
[59] Maija Renko,et al. Critical innovation characteristics influencing the acceptability of a new pharmaceutical product format , 2007 .
[60] Stefan Stremersch,et al. Health and marketing: The emergence of a new field of research ☆ , 2008 .
[61] W. Mitchell. Whether and When? Probability and Timing of Incumbents' Entry into Emerging Industrial Subfields , 1989 .
[62] David M Levinson,et al. First Mover Advantages , 2011 .
[63] J. Avorn,et al. Physician motivations for nonscientific drug prescribing. , 1989, Social science & medicine.
[64] Sriram Venkataraman,et al. The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link? , 2007, Manag. Sci..
[65] Jaap E. Wieringa,et al. Modeling the effects of pharmaceutical marketing , 2010 .
[66] Natalie Mizik,et al. Are Physicians "Easy Marks"? Quantifying the Effects of Detailing and Sampling on New Prescriptions , 2004, Manag. Sci..
[67] P. Berthon,et al. Communication in the salesperson/customer dyad: an empirical investigation , 1998 .
[68] Roland Soong,et al. ‘Ask Your Doctor!’ Measuring the effect of direct-to-consumer communications in the world’s largest healthcare market , 2004 .
[69] W P McKinney,et al. Pharmaceutical representatives in academic medical centers , 1990, Journal of General Internal Medicine.
[70] J. Dawes,et al. What is Differentiation and How Does it Work ? , 2001 .
[71] Joel Lexchin,et al. The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States , 2008, PLoS medicine.
[72] Tammo H. A. Bijmolt,et al. Generalizations on the effectiveness of pharmaceutical promotional expenditures , 2008 .
[73] D. Vakratsas,et al. A dual-market diffusion model for a new prescription pharmaceutical , 2008 .
[74] G. Robert,et al. Diffusion of innovations in service organizations: systematic review and recommendations. , 2004, The Milbank quarterly.
[75] G. Kalyanaram,et al. Order of Market Entry: Established Empirical Generalizations, Emerging Empirical Generalizations, and Future Research , 1995 .
[76] Gregory S. Carpenter,et al. Late Mover Advantage: How Innovative Late Entrants Outsell Pioneers: , 1998 .
[77] G. Lilien,et al. The timing of competitive market entry: an exploratory study of new industrial products , 1990 .
[78] Pradeep K. Chintagunta,et al. Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis , 2004 .
[79] Ira Horowitz,et al. New-product success in the pharmaceutical industry: how many bites at the cherry? , 2005 .
[80] D. Forbes. Principles of Pharmaceutical Marketing , 1975 .
[81] Robert A. Peterson,et al. First-Mover Advantage: A Synthesis, Conceptual Framework, and Research Propositions , 1992 .
[82] Leonard J. Parsons,et al. Analysis of Sales Call Effectiveness , 1981 .
[83] N. Carroll,et al. Consumer responses to direct to consumer prescription drug advertising , 2007 .
[84] G. Kalyanaram,et al. Dynamic Effects of the Order of Entry on Market Share, Trial Penetration, and Repeat Purchases for Frequently Purchased Consumer Goods , 1992 .
[85] Stefan Stremersch,et al. Marketing of the Life Sciences: A New Framework and Research Agenda for a Nascent Field , 2009 .
[86] Morgan P. Miles,et al. A research note on market creation in the pharmaceutical industry , 2011 .
[87] W. S. Comanor,et al. The political economy of the pharmaceutical industry. , 1986, Journal of economic literature.
[88] Vivek Madupu,et al. How did you find your physician , 2009 .
[89] Jennifer S. Lin,et al. Using Existing Systematic Reviews in Complex Systematic Reviews , 2008, Annals of Internal Medicine.
[90] D. Wong-Rieger. Should Canada allow direct-to-consumer advertising of prescription drugs?: yes. , 2009, Canadian family physician Medecin de famille canadien.
[91] S. Tett,et al. Prescription drug samples – does this marketing strategy counteract policies for quality use of medicines? , 2003, Journal of clinical pharmacy and therapeutics.
[92] K. Shojania,et al. How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis , 2007, Annals of Internal Medicine.
[93] Hubert Gatignon,et al. Order of Entry as a Moderator of the Effect of the Marketing Mix on Market Share , 1996 .
[94] K. Leffler,et al. Persuasion or Information? The Economics of Prescription Drug Advertising , 1981, The Journal of Law and Economics.
[95] Ambar G. Rao,et al. Bayesian Estimation and Control of Detailing Effort in a Repeat Purchase Diffusion Environment , 1981 .
[96] G. Tellis,et al. Pioneer Advantage: Marketing Logic or Marketing Legend? , 1993 .
[97] Andrea Coscelli,et al. The Importance of Doctors' and Patients' Preferences in the Prescription Decision , 2003 .
[98] Prof. Dr. Wieland Kiess,et al. Gesundheitsreformen in Deutschland , 2007, Kinder- und Jugendmedizin.
[99] F Davidoff,et al. Systematic Reviews: Critical Links in the Great Chain of Evidence , 1997, Annals of Internal Medicine.
[100] Andrew T. Ching,et al. Understanding Firm, Physician and Consumer Choice Behavior in the Pharmaceutical Industry , 2005 .
[101] David H. Reiley,et al. The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry , 1994 .
[102] David Moher,et al. Epidemiology and Reporting Characteristics of Systematic Reviews , 2007, PLoS medicine.
[103] Jesús Gutiérrez-Cillán,et al. Order, positioning, scope and outcomes of market entry , 2008 .
[104] L. de Chernatony,et al. Winning Hearts and Minds: Business-to-Business Branding and the Role of the Salesperson , 2007 .
[105] Min Ding,et al. A Dynamic Competitive Forecasting Model Incorporating Dyadic Decision Making , 2008, Manag. Sci..
[106] G. Kalyanaram. The endogenous modeling of the effect of direct‐to‐consumer advertising in prescription drugs , 2009 .
[107] B. Jönsson. Flat or monotonic pricing of pharmaceuticals: practice and consequences , 2001, The European Journal of Health Economics (HEPAC).
[108] M. Hollon. Direct-to-consumer marketing of prescription drugs: creating consumer demand. , 1999, JAMA.
[109] Jennifer Rice. Are HMO physicians more price sensitive in prescribing brand‐name drugs? , 2009 .